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Deregulated expression of c-myc and bcl-xL is long known to generate transformed
B cells in humans and mice. We overexpressed these genes to induce in vitro and in vivo
differentiation of fetal liver-derived mouse pre-BI cells to B1-lineage pre-BII-like, imma-
ture and mature B-cell lines, and to Ig-secreting cells. In vitro, doxycycline-controlled
c-myc/bcl-xL-overexpressing CD19+CD93+c-kikt+IgM− pre-BI cells differentiate to and
survive as CD19+CD93+c-kit−IgM+ immature B1 cells. Timed CpG stimulation of these
oncogene-overexpressing pre-B or immature B1 cells generates either CD19+CD93low
c-kit−IgM−SLC− pre-BII-like or IgM+MHCII+CD73+CD80+CD40+ mature B1-cell lines and
IgM-secreting B1 cells in vitro and fixes their state of differentiation. All cell lines are
clonable, but a majority of immature and mature B1-cell clones eventually reach a
nonproliferating, surviving G0-state. Transplanted in vivo, c-myc/bcl-xL-overexpressing
pre-B cells expand to mature B1 cells, and to IgM- and IgA-secreting plasmablasts and
plasma cells.Within 2months, plasmablasts have expandedmost prominently in BM and
spleen, indicating that the host selectively expanded development of these transformed
plasma cells. The sIgM+ B1-cell lines and clones offer the possibility to study their roles
in the development of B1-Ab repertoires, of B1-cell-mediated autoimmune diseases and
of B1-cell malignancies.
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Introduction
Deregulated expression of c-myc is frequently associated with B-
cell transformation in mice and humans, leading to deregulated
cell cycle progression and proliferation, and also to apoptotic cell
death [1]. Co-overexpression of the antiapoptotic gene bcl-xL,
which inhibits the proapoptotic action of c-myc, is sufficient to
induce fully transformed states of B-lymphocyte lineage cells [2].
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In normal murine B-cell development c-myc is highly expressed
in proliferating B-lineage cells, such as pre-BI, large pre-BII, and
stimulated mature B cells, and is downregulated in nonactivated,
resting immature, and na¨ıve mature B cells and plasma cells [3–5].
c-myc regulates a wide variety of cellular processes [6]. By direct
or indirect activation of cell cycle activating genes including
cyclins and cyclin-dependent kinases, or by antagonizing cell cycle
inhibitors, c-myc regulates cell cycle progression and proliferation
[7]. In parallel, by inhibiting the ARF-MDM2-p53 tumor suppres-
sor pathway, c-myc further favors the initiation of apoptosis [8].
bcl-xL, like bcl-2, is thought to protect the mitochon-
drial membrane from releasing cytochrome c after apoptotic
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stimulation [2], thereby inhibiting apoptosis. bcl-xL is expressed
throughout the early mouse B-cell development and becomes
undetectable in mature B cells [9–11]. Furthermore, bcl-xL, but
not bcl-2, is rapidly induced in peripheral B cells upon surface IgM
cross-linking, CD40 signaling, or LPS stimulation [10, 11].
bcl-xL transgenic immature B cells that express self-reactive
BCR, escape central tolerance [12]. bcl-xL has been found overex-
pressed in several types of hematopoietic tumors, including acute
lymphoblastic leukemias [1], non-Hodgkin’s, Hodgkin’s, and HIV-
associated lymphomas, and in acute myelogenous leukemia and
myeloma [13]. B-lineage cell stage-specific, promoter-controlled
targeting of oncogene-overexpression to early or late stages of
B-cell development influences the preferential development of
B-lineage tumors of early, for example, acute lymphoblastic
leukemias, or of late, for example, plasmacytomas and multiple
myelomas [1, 14] in vivo.
Here, we overexpress the cooperating, malignancy-inducing
oncogenes, c-myc and bcl-xL (c-myc/bcl-xL), introduced by
doxycycline-induced retroviral vectors and continuously over-
express these oncogenes from fetal liver-derived mouse pre-BI
cells through all stages of B1-cell development [15]. We follow
the effects of doxycycline-reversible c-myc/bcl-xL-overexpression
on the differentiation of pre-BI cells to B cells and plasma cells
in vitro and, after transplantation into immunodeficient recipient
mice in vivo. We find that under differentiating culture conditions
c-myc/bcl-xL-overexpressing pre-BI cells terminate proliferation,
survive for long periods of time, and increasingly develop within
18 days to immature B1 cells.
We then stimulate in vitro differentiating, c-myc/bcl-xL-
overexpressing B1-lineage cells at different times of differ-
entiation with unmethylated CpG oligodeoxynucleotides (CpG
ODN1826) [16] and with LPSs [17]. Surprisingly, only CpG,
but not LPS stimulates proliferation of early differentiating pre-
B cells, and of in vitro generated immature sIgM+ B cells. Fur-
thermore, CpG-stimulated CD19+CD93+c-kit+SLC+sIgM− pre-BI
cells differentiate to CD19+CD93lowc-kit−SLC−sIgM− pre-BII-like
cells, while CpG-stimulated, in vitro generated immature sIgM+
B cells become sIgM+CD93low/−MHCII+CD73+CD80+CD40+
mature B cells. Our findings indicate that CpG stimulation has
differentiation-inducing effects on c-myc/bcl-xL-overexpressing B-
lineage cells. Additionally, immature sIgM+ B cells that have dif-
ferentiated in vitro for longer than a month can be stimulated by
CpG to secrete IgM in vitro.
When c-myc/bcl-xL-overexpressing pre-BI cells are trans-
planted into RAG−/− mice, expanding pre-B cells, mature B1-cells,
and IgM- and IgA-secreting plasmablasts and plasma cells develop
within 2 months in BM and spleen, unless oncogene expression
is terminated by omitting doxycycline from the drinking water.
Hence, these cell lines offer new experimental opportunities to
study the molecular models and cellular stages of B1-cell devel-
opment in vitro and in vivo, their repertoire development [18],
their contributions to autoimmune diseases [19], and their devel-
opment to B1-cell leukemias [20].
Results
Induction of longevity and differentiation of c-myc/
bcl-xL-overexpressing B-lineage cells in vitro
Fetal liver-derived pre-BI cells constitutively expressing GFP and
high levels of reverse transactivator (rtTA) (GFP-rtTA-pre-BI) were
constructed as previously described in more detail [21, 22]. In the
presence of doxycycline, rtTA activates a tetracycline-inducible
promoter (tetON) [23], that controls expression of c-myc or bcl-
xL, or c-myc and bcl-xL together (c-myc/bcl-xL), joined by 2A
peptide, in self-inactivating retroviral vectors [21] (Supporting
Information 1). These doxycycline-inducible vectors were trans-
duced into the GFP-rtTA-pre-BI cells to generate single- and
double-oncogene-transduced cell lines, which could be selected
for successful retroviral transduction by addition of antibiotics in
the presence of stromal cells (OP9) and IL7. The detailed con-
struction of these cell lines, and the tests for oncogene expres-
sion and for functional changes in cell cycle entry and apop-
tosis are described in Supporting Information 1 and show that
the synergistic overexpression of both oncogenes, c-myc and
bcl-xL, has no effects on in vitro cultured, proliferating pre-BI
cells.
After induction of oncogene-overexpression, differentiation
was induced by removal of OP9 stromal cells and IL7 (Fig. 1A).
Almost all c-myc or bcl-xL single-expressing, as well as c-myc/bcl-
xL double-transduced, nonexpressing pre-BI cells, died within 5–9
of days, as pre-BI cells normally do [24] (Fig. 1B, type-1 and Sup-
porting Information Fig. 1H). By contrast, c-myc/bcl-xL double-
expressing pre-BI cells survived for more than a month (Fig.
1B, type-2). The termination of c-myc/bcl-xL-overexpression by
removal of doxycycline induced rapid apoptosis of all stages of in
vitro differentiation (Fig. 1B).
When c-myc/bcl-xL-overexpressing cells were labeled with
eF670—a cell surface dye that is diluted out as cells divide—a
large fraction remained eF670+ (Fig. 1C), thus did not divide
for 6 days of differentiation. On day 4 of differentiation, only a
small fraction (5%) of the surviving cells was found to prolif-
erate, that is, expressed Ki-67 and lost eF670 label (Fig. 1C and
D, type-2 d4). After 18 days, the majority of the differentiating
cells were Ki-67+ and eF670− (Fig. 1C and D, type-2 d18). An
extrapolation to day 0 of the exponential part of the growth curve
(Fig. 1B, dashed gray line) indicates that a small part of all cells
proliferated (around 1 × 103 in 1 × 106 cells). The growth curves
indicate that initially, the majority of retrovirally transduced cells
are Ki-67− nondividing. The proliferating cells expanded 100-fold
within 7 days, suggesting that these proliferating Ki-67+ cells out-
grew any resting, surviving cells, and that the average cell cycle
time was around 40 h, that is, longer than the 18 h of proliferating
pre-BI cells (Supporting Information Fig. 1F). Hence, all subse-
quent analyses of pools of the in vitro differentiated cells repre-
sent, to a considerable degree, the properties of these proliferating
cells.
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Figure 1. Joint c-myc/bcl-xL-overexpression induces longevity and differentiation of pre-BI to immature B cells in vitro. (A) Experimental schedule
illustrating in vitro differentiation experiments of c-myc/bcl-xL-overexpressing fetal liver-derived pre-BI cells from C57BL/6 mice. The cells were
cultured on OP9 stromal cells and IL7 (OP9/IL7) (gray dashed symbols) in the presence (closed symbols) or absence (open symbols) of doxycycline
(dox). Their differentiation was induced on day 0 by removal of OP9/IL7 (-OP9/IL7), generating type-2 (+dox, mediumd0-22). Type-1 cells represent
the survival of transduced, but doxycycline-noninduced (-dox) pre-BI cells. (B) Absolute numbers of c-myc/bcl-xL-overexpressing type-1 and
type-2 cells were determined by counting using a hemacytometer and Trypan blue exclusion. Dashed line extrapolates exponentially growing
type-2 cells to the initiation of differentiation (day 0). As control, differentiating cells were also cultured in the absence of doxycycline from day
0 or 12 of differentiation (open symbols). (C) Proliferation of day 18–22 differentiating type-2 was measured by labeling the cells with 5 μM cell
eFlour670. On days 1, 4, and 6 (d1–6) after labeling, cell divisionwasmonitored by flow cytometry. (D) Ki-67 expression of type-1 and 2 c-myc/bcl-xL-
overexpressing cells culturedwith or without doxycycline for 4 (d4) and 18 days (d18) in the absence of OP9/IL7 wasmeasured by flow cytometry. (E)
Differentiation of c-myc/bcl-xL-overexpressing CD19+CD93+c-kit+IgM− pre-BI-cell cultures (gray rectangles) to CD19+CD93+c-kit−IgM+ immature-
like B cells (black rectangles) was determined by FACS. (F) RT-PCR of genes expressed during B-cell development in c-myc/bcl-xL-overexpressing
pre-BI cells cultured with (type-1) or without (type-2) OP9/IL7 with (+) or without (−) doxycycline (dox). WT SPL = WT spleen control, M = 1
kb plus size marker. (G) Polyclonal activation of c-myc/bcl-xL-overexpressing, type-2 cells 5 days after stimulation. Significance was determined
comparing polyclonal stimulated and nonstimulated (medium) immature-like B cells by two-tailed unpaired t-test; *p < 0.05, ***p < 0.0005, n.s =
not significant. (B, E, and G) Data are shown as mean ± SEM and are from a single experiment representative of three to six (B–G) independent
experiments with three samples per experiment.
We have previously found that the co-culture of LPS-activated
splenic B cells with rat thymus cells increased the cloning effi-
ciency of proliferating B-cell blasts more than 1000-fold to one
in three blast cells [25]. We employed this cloning protocol to
the c-myc/bcl-xL-overexpressing B1-lineage cell lines to study
the further development of these different cell stages on a
clonal level. Upon single cell sorting on rat thymus cells, one
in four of these type-2 cells were found to form clones (Sup-
porting Information 2, type-2). Some of them continued prolif-
eration; others reverted to long-term survival after 14 days in
culture.
After induction of differentiation, c-myc/bcl-xL-overexpressing
CD19+CD93+c-kit+sIgM− pre-BI cells (type-2) downregulated
c-kit expression, as differentiating nontransduced cells do [24]
(Fig. 1E, detailed gating strategy see Supporting Information
Fig. 3), while sIgM expression became detectable. Between 18
and 22 days, and at least until day 32 of differentiation, the
majority of the c-myc/bcl-xL-overexpressing type-2 cells were
CD19+CD93+c-kit−sIgM+ (Fig. 1E), a phenotype characteristic
for immature B cells [26]. This CD19+CD93+c-kit−sIgM+ imma-
ture B-cell phenotype was monitored on all clones, whether
they continued to proliferate for 32 days, or whether they
ceased to proliferate after additional 14 days (Supporting
Information 4).
In summary, double transduction of pre-BI cells with c-myc
and bcl-xL, and their subsequent differentiation, established long-
term surviving immature B-cell-like cell lines, of which a majority
is resting, nonproliferating, and a minority proliferating.
Polyclonal stimulation of in vitro differentiated
immature B cells
Previous reports have shown that normal, untransduced imma-
ture B cells can functionally be distinguished from mature B cells
by their differential responsiveness to polyclonal activators [26].
When stimulated by IgM-specific antibodies, immature B cells
die by apoptosis, while mature CD19+CD93−sIgM+ B cells are
induced to proliferate. Five days after exposure to IgM-specific
antibodies, 18 days differentiated CD19+CD93+c-kit−IgM+
c-myc/bcl-xL-overexpressing B cells were found reduced in num-
bers, when compared to nonstimulated controls (Fig. 1G). These
results suggest that IgM-specific antibodies convey inhibitory
effects on in vitro differentiated c-myc/bcl-xL-overexpressing
immature-like B cells. By contrast, other polyclonal B-cell activa-
tors, such as LPS- or CD40-specific antibodies did neither inhibit
proliferation nor induced death of nontransduced c-myc/bcl-xL
immature B cells, as it was also shown for WT nontransduced
immature B cells [26] (not shown). Thus, in vitro differentiated
c-myc/bcl-xL-overexpressing immature-like B cells display some
of functional properties of immature B cells.
CpG stimulation of c-myc/bcl-xL-overexpressing
pre-B cells generates pre-BII-like cells in vitro
RT-PCR analyses detected the expression of TLR4, TLR9,
and MyD88 [27] in c-myc/bcl-xL-overexpressing pre-BI cells
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Figure 2. CpG-stimulated c-myc/bcl-xL-overexpressing pre-BI cells expand by proliferation. (A) Experimental schedule illustrating in vitro dif-
ferentiation experiments (see Fig. 1A). Here, c-myc/bcl-xL double-expressing pre-BI cells were additionally stimulated with CpG from day 0 of
differentiation. (B) Growth curves of c-myc/bcl-xL-overexpressing cells differentiating without OP9/IL7, in the presence (closed circles) or absence
(open circles) of doxycycline in medium alone (black circles, type-2) or in the presence of CpG (gray circles, type-3) from day 0 of differentiation.
Live cells were counted using a hemacytometer and Trypan blue exclusion. (C) Percent of proliferating Ki-67+ eF670-labeled type-3 cells on days
(d) 1, 4, 6, and 18 of differentiation was determined by flow cytometry. (D) Summary of FACS analyses showing surface marker expression changes
of c-myc/bcl-xL-overexpressing CD19+CD93+c-kit+IgM− pre-BI cells (gray boxes) to CD19+CD93lowc-kit−IgM− pre-BII-like cells (black/white boxes).
CD19+CD93low/−c-kit−IgM+ immature B cells (black boxes) remained undetectable. (E) Quantitative RT-PCR of surrogate light chain (SLC) compo-
nent λ5 expression in c-myc/bcl-xL-overexpressing pre-BI cells or in c-myc/bcl-xL-overexpressing cell lines differentiating either without (type-2)
or with CpG (type-3), respectively. N.d. = expressed SLCmRNA levels not detected. (F) Intracellular FACS analysis of SLC expression in c-myc/bcl-xL
type-3 cells. White histogram = pre-BI-cell control (positive control). (B, D, and E) Data are shown as mean ± SEM and are from a single experiment
representative of three to six (B–F) independent experiments with three samples per experiment. Significance was determined in B by two-tailed
unpaired t-test, *p < 0.05.
(type-1) and immature B cells (Fig. 1F, type-2). Therefore, we
next stimulated both types of cells either with LPS or CpG
(Fig. 1G). Interestingly, CpG, but not LPS, stimulated increased
proliferation in 95–98% of the double oncogene-overexpressing
cells (Fig. 1G) either differentiated for less than a day (d0)
(Fig. 2A) or for 18 days (d18) (Fig. 3A), shortening the average cell
cycle time from 40 to 18 h, losing eF670-label (Fig. 2B and C), and
expressing high levels of Ki-67 (Fig. 3C). Cells stimulated at day 0
of induction of differentiation by removal of IL7 and OP9 stromal
cells with CpG, downregulated c-kit expression levels within 4 days
of CpG stimulation, while sIgM expression remained undetectable,
either on the cell surface, or in the cytoplasm. Within 9 days of dif-
ferentiation the d0-CpG-stimulated, c-myc/bcl-xL-overexpressing
pre-BI cells became CD19+CD93lowc-kit−IgM− (Fig. 2D). The sur-
rogate light chain (SLC) expression was downregulated on mRNA
and on protein levels (Fig. 2E and F). These results suggest that
the d0-CpG-stimulated pre-BI cells (type-3) became and remained
arrested at a small, DH-JH-rearranged (data not shown) pre-BII-
like stage of B1-cell development.
Type-3 cells were cloned in cultures containing CpG and rat
thymus cells (Supporting Information Fig. 2, type-3). At least two
of three cells yielded clones, all of which continued to prolifer-
ate beyond 2 weeks with average cell cycle times of 18 h. They
retained their CD19+CD93+c-kit−Ki-67+SLC−sIgM− phenotypes
resembling pre-BII-like cells for at least additional 28 days in
cell culture (Supporting Information Fig. 4). This pre-BII-cell-like
phenotype has previously not been detected in normal differenti-
ation of pre-BI cells in vitro [28].
CpG stimulation of c-myc/bcl-xL-overexpressing
immature B cells generates mature B cells in vitro
CpG stimulation of the day 18 differentiated CD19+CD93+
c-kit−SLC−sIgM+ immature B cells (type-2) (Fig. 3A) induced
increased proliferationwith average cell cycle times changing from
40 h to 18 h. It generated a new cell type (type-4) expressing high
levels Ki-67 (Fig. 3B and C) with downregulated CD93 expres-
sion and upregulated expression of costimulatorymolecules CD40,
CD73, CD80, and MHCII [29] (Fig. 3D and E, Supporting Infor-
mation Fig. 4). Like mature B cells [26], these CpG-stimulated
cells lost the sensitivity to be inhibited by IgM-specific antibodies
(Fig. 3F). These results indicate that CpG stimulation had induced
immature B cells to become mature B cells.
After single cell sorting on rat thymus cells, one in six type-4
cells were capable to establish large CpG-stimulated clones with at
least 104 cells/clone in 14 days (Supporting Information 2, type-
4). Clones with smaller numbers of cells (0.5 × 104 and less) were
also detectable (approximately one in 2–3), but they were not
investigated further. Approximately 90% of the CpG-stimulated
mature B-cell clones terminated proliferation shortly after collec-
tion and survived as Ki-67− cells (Supporting Information Fig. 2B
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Figure 3. c-myc/bcl-xL-overexpressing immature B cells generated in vitro for 32 days differentiate to IgM-secreting cells upon stimulation with
CpG or with CpG and CD40/IL-4. (A) Experimental schedule (see also Fig. 1A). c-myc/bcl-xL-overexpressing pre-BI cells were cultured with CpG
(gray filled symbols) either from day 18 or day 32 of differentiation, generating type-4, type-5, or type-6 cell lines, respectively. (B) Proliferation
of c-myc/bcl-xL-overexpressing B cells cultured in the presence (closed circles) or absence (open circles) of doxycycline in medium alone (black
circles, type-5) or in the presence of CpG from day 18 of differentiation (black/gray circles, type-4) was determined by flow cytometry. (C) Ki-67
staining of type-4 and type-5 c-myc/bcl-xL cells cultured for 32 day with or without doxycycline was assessed by flow cytometry. (D) Summary
of FACS analysis illustrating the surface marker expression of CD19+CD93+c-kit+IgM− pre-BI cells (gray box) and CD19+CD93low/−c-kit−IgM+
B-lineage cells (black box). (E) CD40, CD80, and MHCII surface marker expression of type-4 and type-5 B cells. Representative flow histograms are
shown. (F) Mitogen response 5 days after polyclonal stimulation of type-4 or type-5 cells. Significance was determined comparing CpG-stimulated
type-4 to type-5 B cells by two-tailed unpaired t-test; **p < 0.005. (G) ELISA analysis of secreted IgM in supernatants of 1 × 104 type-4 or type-6
bulk cell populations stimulated for 5 days either with (+) or without (−) CpG and/or CD40 and/or IL-4. Significance was determined comparing
nonstimulated (medium) to stimulated cells by two-tailed unpaired t-test; **p < 0.005, n.s. = not significant. (B, D, F, and G) Data are shown as
mean ± SEM and are from a single experiment representative of three to six independent experiments with three samples per experiment.
and C). Ten percent of clones continued CpG-stimulated prolif-
eration with average cell cycle times of 18 h. All surviving and
proliferating clones were CD19+CD93low/−, that is, displayed a
mature B-cell phenotype. The clones retained this phenotype for
additional 32 days of in vitro culture (Supporting Information Fig.
4, type-4). These results surprisingly suggest that a large part of
CpG-stimulated mature B cells are no longer capable to proliferate
in response to CpG. They appeared to reach a nonproliferating G0-
like cell cycle state that only becomes detectable because clones
of these cells gain long-term survival capacity through the overex-
pression of c-myc and bcl-xL.
CpG stimulation of c-myc/bcl-xL-overexpressing,
immature B cells generates IgM secreting cells in vitro
The CpG-dependent development of mature B-cell markers
prompted an analysis of their capacity to secrete Ig. Therefore,
after 18 days of differentiation, we cultured the differentiated
B-lineage cells either in the presence or absence of CpG for another
14 days. Thereafter, CpG, CD40-specific Ab, and/or IL-4 were
added for 5 days, generating conditions that have been shown
to induce polyclonal mature B cells proliferate and to switch the
IgM isotypes to IgG1 and IgE (Fig. 3A) [30]. Five days after stim-
ulation, secreted Ig was monitored in the supernatant medium by
ELISA (Fig. 3G).
Immature B cells (type-2) differentiated for 18 days did not
secrete significant amounts of Ig under any of the chosen stimula-
tion conditions. Mature B cells (type-4) that differentiated for 18
days without and for 14 days with CpG did not secrete detectable
amounts of IgM, IgG, IgE, or IgA nor did they do so after stimu-
lation with CD40-specific antibodies and IL-4. However, surpris-
ingly, 1 × 104 immature B cells that had differentiated for more
than 32 days without CpG (type-5), and which were then stim-
ulated for 5 days with CpG, generating a type-6 cell type, were
found to secrete 240–380 ng/mL IgM, while IgG or IgE secretion
remained undetectable. Furthermore, the combined stimulation
by CpG, CD40-specific antibodies, and IL-4 increased the levels
of IgM to 440–800 ng/mL. IgG, IgA, and IgE secretion remained
undetectable.
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We conclude that the differentiation of c-myc/bcl-xL-
overexpressing immature B cells continues for several weeks in
vitro in the absence of CpG, allowing the development of cells
that can be induced by CpG or by combining CpG and CD40-
specific antibodies and IL-4 to secrete IgM. Addition of CpG at
earlier times, for example, at 18 days of differentiation, appeared
to inhibit this capacity to be stimulable by CpG, CD40-specific
antibodies, and IL-4 to secrete IgM. Our results point to a surpris-
ing capacity of B1 cells stimulated for extended periods of time
to develop capacities to secrete antibodies. The cell lines, which
we have generated, should be useful tools to study the molecu-
lar modes, by which CpG-induced TLR9 signaling develops this
capacity of B1 cells to secrete.
c-myc/bcl-xL pre-BI-cell transplantation into
immunodeficient RAG−/− mice
When normal fetal liver-derived pre-BI cells are transplanted into
RAG−/− mice, they populate the spleen as CD5− and the peri-
toneum as CD5+ B1-cells, but not the BM of the host [31, 32].
Transplantations of c-myc- or bcl-xL-single-expressing pre-BI cells
into doxycycline-fed RAG−/− mice do not alter this transplantation
behavior [21, 22].
However, when the GFP+ c-myc/bcl-xL double-oncogene-
expressing pre-BI cells were transplanted here into RAG−/− mice
(Fig. 4A), GFP+ cells were detected not only in the spleen,
but also in the BM of doxycycline-fed mice (Fig. 4B). At least
ten- to 15-fold increased numbers of GFP+ were detected within
4 weeks, and 100- to 1000-fold higher numbers after 8 weeks of
transplantation, when compared to control mice, which received
no doxycycline in their drinking water. Most of these GFP+ cells
were Ki-67+, a sign that the transplanted cells expanded, causing
splenomegaly (Fig. 4C and D).
The phenotypes of expanded GFP+ c-myc/bcl-xL cells were
analyzed by FACS analyses (Fig. 4E). Pre-BI cells, immature B
cells, mature B1 cells, and cells with phenotypes resembling plas-
mablasts and terminally differentiated plasma cells were detected
in BM and spleen (Fig. 4E). Notable was the selective, up to 104-
fold increase of plasmablast- and plasma cell-like cells 8 weeks
after transplantation. Consistent with the detection of elevated
numbers of plasmablasts and plasma cells, slightly higher than
normal levels of IgM (350 ng/mL) and nearly normal levels of
IgA (100 ng/mL), but only low levels of IgG (80 ng/mL) were
detected (Fig. 4F). Hence, in contrast to the in vitro differentiation
of Ig-secreting cells, these c-myc/bcl-xL-overexpressing cells also
secreted IgA, but no IgG in vivo. This is in line with previous obser-
vations that normal fetal liver-derived pre-BI cells restore normal
levels of IgA but no IgG, when transplanted into immunodeficient
mice [24].
When the in vivo oncogene expression was terminated 8 weeks
after transplantation by removing doxycycline from the drink-
ing water, the expansion of GFP+ cells could be reversed within
the next 4 weeks (Fig. 4B and E). Hence, the in vivo expanded
double oncogene-transduced plasmablast- and plasma cell-like
populations were reduced as much as 103-fold to low residual lev-
els, that is, below 104 cells each in BM and spleen. Thus, prolifera-
tion, differentiation, and survival of a large majority of c-myc/bcl-
xL-transformed cells depended on oncogene-overexpression. In
line with the reduced cell numbers of plasmablast and plasma
cells, the levels of secreted IgM and IgA were 100-fold reduced 4
weeks after termination of oncogene-overexpression.
These results suggest that the in vivo environment of the host
allows not only the differentiation of oncogene-overexpressing
pre-BI cells to differentiated B-cell stages seen in the in vitro
development, but also promotes their proliferative expansion and
differentiation to Ab-secreting plasmablasts and plasma cells.
Discussion
Fetal liver-derived mouse pre-BI-cell lines as a source of B1-type B-
lineage cells [15] are excellent targets for in vitro transductions by
retroviral vectors, because they proliferate in the presence of IL7
and on stroma cells [24] or on plate-immobilized recombinant Kit-
ligand [33] for long periods of time and do not differentiate. Upon
removal of growth-supporting factors, these pre-BI cells terminate
proliferation and start to differentiate to immature B cells, which,
however, die within a couple of days by apoptosis.
The combined transgenic overexpression of c-myc and bcl-2
was first shown by Vaux et al. [34] to transform mouse pre-
B cells, and these studies were later extended to an analysis of
multiple stages of B-cell development, suggesting, that synergy
of bcl-2 and c-myc effects hyperproliferation of pre-B and B cells
and accelerated development of B-lineage tumors, which, in the
case of bcl-2/c-myc double transgenic mice might derive from a
hematopoietic progenitor cell, maybe a lymphoid-committed pro-
genitor. Our studies suggest that pre-B cells can be the origins of
long-term proliferating cell lines, which, upon transplantation are
supported by the host environment to develop into plasma cell
tumors. The role of bcl-xL instead of bcl-2 was first investigated
by Chao et al. [35], who first found that bcl-xL and bcl-2 repress
a common pathway of cell death in B-lineage cells.
From Eμ-bcl2-myc transgenic mice Strasser et al. [36, 37]
generated cell lines with lymphomyeloid differentiation poten-
tial, which need the support of stromal cells to survive in culture.
Our cell lines differ from these lines, as they are generated by bcl-
xL-myc transduction of more restricted B-lymphoid differentiation
potential that, upon differentiation, survive in culture without the
help of stromal cells or cytokines as immature, eventually IgM+
B cells. Hence, as suggested by Strasser et al., earlier bipoten-
tial lymphomyeloid progenitors need additional factors to survive
and differentiate in culture, while our experiments show that B-
lymphoid-committed cells do not need these factors any longer to
survive.
The cell lines, which we have generated by combined over-
expression of c-myc and bcl-xL are long lived, but may be not
immortal, since they might shorten their telomeres with contin-
ued proliferation. In fact, we have previously found that in vitro
propagated Pax5-deficient as well as WT pre-B cells shorten their
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Figure 4. Expansion and differentiation of fetal liver-derived c-myc/bcl-xL-overexpressing pre-BI cells in vivo. (A) Transplantation schedule of
GFP+ c-myc/bcl-xL pre-BI cells, cultured on OP9 cells and IL7 in vitro, into doxycycline-fed (+dox, closed bars) and nonfed (-dox, open bars),
sublethally irradiated RAG−/− mice. Eight weeks after transplantation, doxycycline was removed from the drinking water of one group of these
mice (black/white shaded bars). Four (gray bars), 8 (black bars), and 12 (black/white shaded bars) weeks after transplantation, the recipients were
sacrificed, and GFP+ cells from BM (one hind leg = tibia and femur) and spleen were analyzed. (B) Detection of GFP+ c-myc/bcl-xL B-lineage
cells from the designated organs at defined time points was performed by FACS. (C) Ki-67 staining of BM-derived GFP+ cells from doxycycline-
fed (closed histogram) and nonfed (open histogram) recipients was assessed by flow cytometry 4 weeks after transplantation. (D) Spleens from
doxycycline-fed and nonfed recipients, 4 weeks after injection of GFP+ c-myc/bcl-xL pre-BI cells. (E) Cell surface expression analysis of BM-
and spleen-derived GFP+ cells: gating for CD19+CD93+c-kit+sIgM− pre-BI cells, CD19+CD93+c-kit−sIgM+ immature B-, CD19+CD93−c-kit−sIgM+
mature B1 cells, CD19+/lowCD138+sIgM+IgκL+MHCII+TACI− plasmablast, and CD19low/−CD138+sIgMlow/−IgκLlow/−MHCII−TACI+ plasma cells. (F)
ELISA analysis of IgM, IgA, and total IgG detected in sera of transplanted mice at the designated time points after transplantation. Sera from
RAG−/− and WT C57BL/6 were used as controls. (B, E, and F) Data are shown as mean ± SEM and are representative of three independent
experiments with n = 3 mice per experiment. Statistical significance was determined by one-way ANOVA (B, E) and two-tailed unpaired t-test (F);
*p < 0.05, **p < 0.005, ***p < 0.0005.
telomeres by 70–90 bp per division, while they do not express
sufficient telomerase activity to make up for this loss [38]. Since
mouse telomeres are 60 kb long, we have previously estimated
that such cell lines could divide 600 times, that is, at division
times of 18 h for more than a year, before they lose their capacity
to proliferate.
It is interesting to note that our fetal liver pre-B-cell-derived
immature sIgM+ B-cell lines have kappa-L- and lambda L-Ig gene
loci rearranged in expected frequencies (around 90%:10%), but
do not continue in culture to rearrange in high frequencies kappa-
L- and lambda-L-Ig gene loci in secondary rearrangements, as
it has been found with bcl-2 transgenic immature B cells [39],
although they continue to express lower, but detectable lev-
els of RAG1 and 2 (unpublished). This differential behavior of
immature B cells could be due to the difference in oncogene
expression (bcl-xL versus bcl-2), a difference of B-lineage (B1
versus B2), or a difference of in vitro (this study) versus in
vivo (BM derived) isolated immature B cells [39]. Future stud-
ies will have to investigate this differential behavior by com-
parison of bcl-2 with bcl-xL single, or with bcl-2 or bcl-xL-
myc double transgenic immature B cells from fetal liver and
BM ex vivo/in vitro from the appropriate transgenic mice, or
with immature B cells generated from fetal liver-derived or BM-
derived double transgenic pre-B-cell lines, once they become
available.
By overexpressing c-myc and bcl-xL in differentiating pre-BI-
cell lines, and timed stimulation with CpG, we here present a new
method that has allowed us to establish stable, long-term surviv-
ing and proliferating immature B (type-2), pre-BII-like (type-3),
mature B cell (type-4) cell lines, and IgM-secreting cell s (type-6)
from fetal liver-derived B1-lineage pre-BI cells (Fig. 5). Thus, our
study provides a unique protocol to generate cell lines represent-
ing various stages of B1-cell development, which offer a system to
study the ontogeny of these cells.
We have recently been able to establish pre-BI-cell lines from
the BM as possible source for conventional B2-type B cells [33].
This oncogene-overexpression will allow us in the future to com-
pare the developments of oncogene-transduced B1- and B2-type
B cells, their repertoire selection, contribution to autoimmunity
and autoimmune diseases, and to the development of different
B-cell leukemias.
CpG stimulationwas previously found to develop IgM-secreting
B cells from ex vivo cultured spleen- or blood-derived transitional,
na¨ıve mature, or memory conventional B2-type B cells [40–42].
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Figure 5. Generation of different cell lines from in vitro
differentiating c-myc/bcl-xL-overexpressing fetal liver-
derived B1-type pre-BI cells. After initial stimulation, the
pre-BII-like cells (type-3), mature B1-cells (type-4), and
IgM-secreting B1-cells (type-6)were continuously cultured
in the presence of CpG.
Our studies expand the spectrum of CpG-reactive B-lineage cells to
B1-lineage pre-B cells, mature and immature B cells with capacities
to differentiate to Ig-secreting B cells in vitro and in vivo. Future
experiments should attempt to overexpress the two oncogenes
in precursors B cells of marginal zone and conventional B2-type
B cells to evaluate possible functional differences of pre-BII-like,
mature and immature B and Ig-secreting cells developed from
them.
Normal B-cell development from pre-BI cells to Ig-secreting
plasma cells occurs, in considerable parts, in resting cells with-
out proliferation [28]. In pre-B cells, functional Ig μ heavy chains
assemble with SLC as pre-B-cell receptors (preBcR), which are
deposited on the cell surface [43]. PreBcRs stimulate a prolif-
erative burst of large pre-BII-cells, which comes to rest, as SLC
expression is turned off, and preBcR expression is terminated.
This proliferative burst does not occur, when pre-BI cells are
induced in vitro to differentiate. In fact, these differentiating
cells die rapidly by apoptosis. Furthermore, immature and na¨ıve
mature B cells have short half-lives even in vivo [44]. We find
that co-overexpression of c-myc and bcl-xL rescues differentiat-
ing B-lineage cells from this apoptosis in vitro. Most of these c-
myc/bcl-xL-overexpressing, differentiating cells remain resting in
vitro for at least a week. A small subpopulation of the immature
B-cell pool begins to expand by proliferation in vitro. The small
numbers of proliferating immature B cells might carry retroviral
inserts at sites in the genome that control proliferation and that are
activated by the inserts. Since we have been able to separate these
proliferating, eF670-dye-diluting cells from these nonproliferat-
ing, eF670-dye-retaining cells, future experiments should be able
to identify such retroviral inserts in the proliferating immature
B-cell clones and determine the nature of affected genes and their
functions.
Immature B cells react to autoantigenic stimulation by apop-
tosis [28]. In this process of negative repertoire selection, the
autoreactive B cells are deleted, establishing central tolerance.
We have previously seen that IgM+ immature B cells are induced
to apoptosis by IgM-specific antibodies [26]. Here we show that
c-myc/bcl-xL-overexpressing sIgM+ immature B cells are inhib-
ited from further expansion by IgM-specific antibodies in vitro.
It suggests that they perceive sIgM-mediated stimulation as neg-
ative signals. Since we have been able to clone individual, that
is, mAb-producing B-lineage cells, future experiments with a
collection of such clones could determine their recognition of
foreign Ags and autoantigens. This would allow testing a pos-
sible positive or negative reaction to foreign or autoantigens
to individual B-cell clones in vitro and in vivo and the influ-
ence of IgM B-cell receptor (BCR) on the in vivo development
of plasma cell tumors after transplantation. Such experiments
might be able to shed light on the role of the BCR expressed
in B1 cells in development of Ab repertoires, of B-cell- and Ab-




Pre-BI cells were isolated from fetal liver of C57BL/6 mice on day
18 of gestation as previously described [21]. The rtTA-transduced
pre-BI cells, OP9 stroma cells, and Plat-E packaging cell line
(Life Technologies) were cultured, transfected, transduced, and
differentiated as previously described [21, 45]. Differentiation
of pre-BI cells was induced upon removal of OP9 stroma cells
and IL7. Stimulation of 0.5 × 106 cells with 0.1 μM CpG
ODN 1826 (Miltenyi Biotec), 2% recombinant IL-4 supernatant
(in house [46]), LPS, CD40- (clone FGK), or IgM-specific Ab
was performed as described previously [21]. For proliferation
assay, the cells were labeled with eF670 proliferation dye as
recommended by the manufacturer (eBioscience).The Ki-67
staining was performed as recommended by the manufacturer
(eBioscience).
Cell cycle analysis
After 2 days differentiation, 1 × 106 cells were fixed in 70% ice-
cold ethanol at −20°C and stained with 10 μg/mL DAPI (Roth)
in PBS. DAPI was recorded in linear mode by FACS and cells in
S/G2/M phases were gated manually.
AnnexinV staining
On day 2 of differentiation, doxycycline-treated and nontreated
cells were stained with AnnexinV-Cy5 (BD Pharmingen) according
manufacturer’s protocol.
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Vectors
Doxycycline-inducible, “TreTight”-TetOn-controlled [23] SIN
retroviral vectors encoding c-myc and/or bcl-xL were constructed
as reported [21, 22] (Supporting Information 1).
Western blot and flow cytometry
Western blot and flow cytometry were performed as previously
described [21, 22]. For c-Myc detection, the membranes were
probed with mouse anti-c-Myc (clone 9E10, Santa Cruz Biotech),
while bcl-xL detectionwas performedwith rabbit anti-bcl-xL (poly-
clonal, Cell Signaling).
Semiquantitative and quantitative real-time RT-PCR
Total RNA was purified using TRIzol R© Reagent (Life Technolo-
gies). RNA was reverse transcribed using SuperScript III reverse
transcriptase (Life Technologies). RT-PCR was performed using
Taq DNA Polymerase (Thermo Fisher Scientific) according toman-
ufacturer’s protocol. Quantitative RT-PCR was conducted with
QuantiTect SYBR Green PCR Kit (Qiagen). Amplification was per-
formed using following primers:
Myc-hybr (Supporting Information 1) 5′-CGGATTCTCTGCTC
TCCTCGAC-3′ and 5′-CGTCGAGGAGAGCAGAGAATCC-3′,
Gapdh 5′-TTGAGGTCAATGAAGGGGTC-3′ and 5′-TCGTCCCG
TAGACAAAATGG-3′,
MyD88 5′-CACTCGCAGTTTGTTGGATG-3′ and 5′-CACTCGCAG
TTTGTTGGATG-3′,
TLR4 5′-CAAGGGGTTGAAGCTCAGAT-3′ and 5′-TTCTTCTCC
TGCCTGACACC-3′,
TLR9 5′-GGCTTCAGCTCACAGGGTAG-3′ and 5′-GAATCCTCC
ATCTCCCAACA-3′,
SLC 5′-CCGTGGGATGATCTGGAACA-3′ and 5′-TCAGCAGAA
AGGAGCAGAGC-3′
Transplantation of pre-BI and differentiated cells into
RAG−/− recipients
All animal procedures were conducted in compliance with the
German animal protection laws with the protocol approved by
the Landesamt fur Gesundheit und Soziales, Berlin (G0140-11) as
previously described [22].
ELISA
Ig levels of cell culture supernatants and serum samples, compared
with standard Ig class samples, were determined with Maxisorp
ELISA 96-well plates coated with goat antimouse IgM or total IgG
as prescribed by Southern Biotech, Birmingham AL, USA. Using
AP-labeled goat antimouse IgM-AP, or total IgG-AP Ab (Southern
Biotec) the serum Igs were quantified.
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